NCT07213778ClinicalTrials.gov
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
A Phase 3, Multicenter, Double-Blinded, Randomized Study to Evaluate REGN7508, a Factor XI Monoclonal Antibody, Versus Acetylsalicylic Acid for Prophylaxis of Symptomatic Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-ASPEN)
باختصار
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called Acetylsalicylic Acid (ASA). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim…
المرحلة 3مطلوب 2,000 مشارك57 موقعاً5 دول
الفئات
مسجَّلة في سجل واحد
- ClinicalTrials.govNCT07213778فتح هذا السجل في ClinicalTrials.govتمت المزامنة أول أمس
يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.
تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.
هل أنت مهتم بهذه الدراسة؟
تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2025-10-09; recorded start 2025-11-24
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 264 other studies in this databaseCounted from the lead sponsor named in the record (Regeneron Pharmaceuticals)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type10/10
Mortality / MACE endpoint (hard clinical outcome)
- Multi-centre8/8
Multi-centre: 32 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study, international in scope: 2,000 participants (target), run at 57 sites, across 5 countries.
How this score is built
- Enrolment33/40
2,000 participants (target)
- Site count18/25
32 sites
- Country count7/15
4 countries
- Planned duration6/10
Planned over about 20 months
- Sponsor scale9/10
Regeneron Pharmaceuticals has led 248 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
ملخص
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called Acetylsalicylic Acid (ASA). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery compared to acetylsalicylic acid. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
الحالات
- Symptomatic Venous Thromboembolism (VTE)
الأهلية
| الجنس | الجميع |
|---|---|
| الأعمار | 18 Years – لا حد أقصى |
| المتطوعون الأصحّاء | لا |
الأهلية كما كُتبت في السجل
الأهلية في عبارات بسيطة
لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.
تصميم الدراسة
| نوع الدراسة | تدخّلية |
|---|---|
| المرحلة | المرحلة 3 |
| التخصيص | معشّاة |
| نموذج التدخّل | PARALLEL |
| الغرض الأساسي | TREATMENT |
| التعمية | QUADRUPLE (4) |
| التجنيد | مطلوب 2,000 مشارك |
الجهة الراعية والمتعاونون
- Regeneron Pharmaceuticals الجهة الراعية
الأذرع والتدخلات
- REGN7508 and PlaceboEXPERIMENTAL
- Placebo and ASAACTIVE_COMPARATOR
التدخلات
- دواء Acetylsalicylic Acid (ASA)
Administered per the protocol
- دواء Placebo
Administered per the protocol
- دواء REGN7508
Administered per the protocol
مقاييس النتائج
مقياس النتيجة الأولي
Incidence of the composite endpoint of symptomatic VTE and all-cause death
الإطار الزمني Through day 30 visit
مقياس النتيجة الثانوي
Time to first event of the composite endpoint of symptomatic VTE and all-cause death
الإطار الزمني Through day 30 visit
مقياس النتيجة الثانوي
Incidence of confirmed symptomatic Deep Vein Thrombosis (DVT)
الإطار الزمني Through day 30 visit
مقياس النتيجة الثانوي
Incidence of confirmed Pulmonary Embolism (PE)
الإطار الزمني Through day 30 visit
مقياس النتيجة الثانوي
Incidence of all-cause death
الإطار الزمني Through day 30 visit
مقياس النتيجة الثانوي
Time to first event of the confirmed symptomatic DVT
الإطار الزمني Through day 30 visit
مقياس النتيجة الثانوي
Time to first event of the confirmed PE
الإطار الزمني Through day 30 visit
مقياس النتيجة الثانوي
Time to the all-cause death
الإطار الزمني Through day 30 visit
مقياس النتيجة الثانوي
Incidence of the composite endpoint of major bleeding and Clinically Relevant Non-Major (CRNM) bleeding
الإطار الزمني Through day 30 visit
مقياس النتيجة الثانوي
Incidence of minor bleeding
الإطار الزمني Through day 30 visit
مقياس النتيجة الثانوي
Incidence of Treatment-Emergent Adverse Events (TEAEs)
الإطار الزمني Through day 90 visit
مقياس النتيجة الثانوي
Severity of TEAEs
الإطار الزمني Through day 90 visit
مقياس النتيجة الثانوي
Incidence of Anti-drug Antibody (ADA) to REGN7508
الإطار الزمني Through day 90 visit
مقياس النتيجة الثانوي
Magnitude of ADA to REGN7508
الإطار الزمني Through day 90 visit
مقياس النتيجة الثانوي
Concentrations of REGN7508
الإطار الزمني Through day 90 visit
التواريخ
| تاريخ البدء | 24 نوفمبر 2025 (فعلي) |
|---|---|
| الإتمام الأولي | 17 مايو 2027 (تقديري) |
| الإتمام | 16 يوليو 2027 (تقديري) |
| أول نشر | 9 أكتوبر 2025 (فعلي) |
| آخر تحديث | 19 نوفمبر 2026 |
| النتائج منشورة | غير مذكور في سجل السجل |
| آخر تأكيد للحالة | نوفمبر 2026 |
فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.
المواقع
54 موقعاً قيد التجنيد
Greece
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Henry Dunant Hospital Center | Athens | Attica | قيد التجنيد |
| National and Kapodistrian University of Athens, General Hospital of Nea Ionia Konstantopouleio Patision | Nea Ionia | Attica | قيد التجنيد |
| Papageorgiou General Hospital of Thessaloniki | Thessaloniki | Central Macedonia | قيد التجنيد |
Malaysia
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Hospital Pakar Universiti Sains Malaysia | Kota Bharu | Kelantan | قيد التجنيد |
| Hospital Queen Elizabeth II | Kota Kinabalu | Sabah | قيد التجنيد |
| Universiti Malaya Medical Centre | Kuala Lumpur | Kuala Lumpur | قيد التجنيد |
| Hospital Tengku Ampuan Afzan (HTTA) | Kuantan | Pahang | قيد التجنيد |
| Sultan Abdul Halim Hospital | Sungai Petani | Kedah | قيد التجنيد |
Moldova
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| PMSI Emergency Medicine Institute | Chisinau | قيد التجنيد |
Spain
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Hospital Clinic Barcelona | Barcelona | قيد التجنيد | |
| Hospital Universitario Infanta Leonor | Madrid | قيد التجنيد | |
| Hospital Universitario Costa del Sol | Marbella | Malaga | قيد التجنيد |
| Clinica Universidad de Navarra | Pamplona | Navarre | قيد التجنيد |
| Hospital Clinico Universitario de Valencia | Valencia | قيد التجنيد | |
| Hospital Miks Ospitalea | Vitoria-Gasteiz | Araba/Alava | قيد التجنيد |
United States
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Velocity Clinical Research, Annapolis | Annapolis | Maryland | قيد التجنيد |
| Sinai Hospital of Baltimore, Inc. | Baltimore | Maryland | قيد التجنيد |
| Mercy Medical Center | Baltimore | Maryland | قيد التجنيد |
| Boston Medical Center | Boston | Massachusetts | قيد التجنيد |
| Tufts Medical Center | Boston | Massachusetts | قيد التجنيد |
| Atrium Health Musculoskeletal Institute and Sports Medicine | Charlotte | North Carolina | قيد التجنيد |
| University of Cincinnati | Cincinnati | Ohio | قيد التجنيد |
| Ohio Clinical Trials | Columbus | Ohio | قيد التجنيد |
| The Ohio State University Wexner Medical Center | Columbus | Ohio | قيد التجنيد |
| South Florida Joint Replacement Center | Deerfield Beach | Florida | قيد التجنيد |
| Delray Physician Care Center | Delray Beach | Florida | قيد التجنيد |
| Duke University Health System (Duke Health), Duke University Hospital | Durham | North Carolina | قيد التجنيد |
| HCA HealthONE Centennial | Englewood | Colorado | قيد التجنيد |
| Penn State Health Milton S. Hershey Medical Center | Hershey | Pennsylvania | قيد التجنيد |
| NextStage Clinical Research, All American Orthopedics and Sports Medicine | Houston | Texas | قيد التجنيد |
| HD Research - Memorial Hermann Village | Houston | Texas | مكتمل |
| The Orthopaedic Research Foundation, Inc. | Indianapolis | Indiana | قيد التجنيد |
| Horizon Clinical Research | La Mesa | California | قيد التجنيد |
| HCA HealthONE, HCA HealthONE Sky Ridge | Lone Tree | Colorado | قيد التجنيد |
| Futuro Clinical Trials | McAllen | Texas | قيد التجنيد |
| Medical Research of Westchester - MPLUS Research Network | Miami | Florida | مسحوب |
| Northwell Orthopaedic Institute | New York | New York | قيد التجنيد |
| NYU Langone | New York | New York | قيد التجنيد |
| University of Pittsburgh | Pittsburgh | Pennsylvania | قيد التجنيد |
| Keystone Clinical Studies LLC, dba Flourish Research | Plymouth Meeting | Pennsylvania | قيد التجنيد |
| Eximia Equihealth Research-Raleigh. LLC | Raleigh | North Carolina | قيد التجنيد |
| The Vein and Vascular Center at Raleigh Radiology | Raleigh | North Carolina | قيد التجنيد |
| Eisenhower Medical Center | Rancho Mirage | California | قيد التجنيد |
| CARI Clinical Trials | Riverside | California | قيد التجنيد |
| Carilion Clinic | Roanoke | Virginia | قيد التجنيد |
| University of Rochester Medical Center | Rochester | New York | قيد التجنيد |
| Flourish Research - San Antonio (Formerly Clinical Trials of Texas) | San Antonio | Texas | قيد التجنيد |
| Endeavor Clinical Trials | San Antonio | Texas | مسحوب |
| Endeavor Health | Skokie | Illinois | قيد التجنيد |
| Larkin Community Hospital South Miami | South Miami | Florida | قيد التجنيد |
تُدرَج 7 مواقع إضافية في سجل السجل.
مستندات الدراسة
لا تُرتبط أي مستندات في سجل السجل هذا.
التغيّرات عبر الزمن
- 5 نوفمبر 2026
أُضيف موقع
6 sites added (57 total)
5157
- 22 أكتوبر 2026
أُضيف موقع
2 sites added (51 total)
4951
- 8 أكتوبر 2026
أُضيف موقع
3 sites added (49 total)
4649
- 25 سبتمبر 2026
أُضيف موقع
10 sites added (46 total)
3646
- 14 سبتمبر 2026
أُضيف موقع
2 sites added (36 total)
3436
- 19 أغسطس 2026
أُضيف موقع
2 sites added (34 total)
3234